| Item Type | Name |
|
Academic Article
|
Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms.
|
|
Concept
|
Thrombocytopenia
|
|
Academic Article
|
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.
|
|
Academic Article
|
Splenectomy in the accelerated or blastic phase of chronic myelogenous leukemia: a single-institution, 25-year experience.
|
|
Academic Article
|
Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia.
|
|
Academic Article
|
Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications.
|
|
Academic Article
|
Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy.
|
|
Academic Article
|
Results of topotecan-based combination therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
|
|
Academic Article
|
A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia.
|
|
Academic Article
|
The incidence and impact of thrombocytopenia in myelodysplastic syndromes.
|
|
Academic Article
|
The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
|
|
Academic Article
|
JAK2 inhibitors: A reality? A hope?
|
|
Academic Article
|
Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes.
|
|
Academic Article
|
Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.
|
|
Academic Article
|
Fludarabine: a new agent with major activity against chronic lymphocytic leukemia.
|
|
Academic Article
|
Cis-diaminodichloroplatinum (II) chemotherapy for advanced adenocarcinoma of the upper gastrointestinal tract.
|
|
Academic Article
|
Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase.
|
|
Academic Article
|
Myeloid markers in adult acute lymphocytic leukemia. Correlations with patient and disease characteristics and with prognosis.
|
|
Academic Article
|
Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia.
|
|
Academic Article
|
Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients.
|
|
Academic Article
|
The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells.
|
|
Academic Article
|
Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.
|
|
Academic Article
|
Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia.
|
|
Academic Article
|
Thrombocytopenia in patients with myelodysplastic syndromes.
|
|
Academic Article
|
Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy.
|
|
Academic Article
|
Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system.
|
|
Academic Article
|
Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study.
|
|
Academic Article
|
Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.
|
|
Academic Article
|
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.
|
|
Academic Article
|
High-dose cytosine arabinoside: treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis.
|
|
Academic Article
|
The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase.
|
|
Academic Article
|
Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure.
|
|
Academic Article
|
Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia.
|
|
Academic Article
|
Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes.
|
|
Academic Article
|
Difluoromethylornithine and leukocyte interferon: a phase I study in cancer patients.
|
|
Academic Article
|
Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic Myelogenous leukemia.
|
|
Academic Article
|
Lenalidomide therapy in myelofibrosis with myeloid metaplasia.
|
|
Academic Article
|
Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial.
|
|
Academic Article
|
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia.
|
|
Academic Article
|
The incidence and impact of thrombocytopenia in myelodysplastic syndrome
|
|
Academic Article
|
Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes.
|
|
Academic Article
|
A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms.
|
|
Academic Article
|
Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis.
|
|
Academic Article
|
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial.
|
|
Academic Article
|
Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy.
|
|
Academic Article
|
Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial.
|
|
Academic Article
|
Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia.
|
|
Academic Article
|
Freeze-dried platelets are a promising alternative in bleeding thrombocytopenic patients with hematological malignancies.
|
|
Academic Article
|
Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study.
|